Pipeline Overview
Stabilized Injectable Formulation (SIF)
| Product / Indication | Research | Pre-clinical | Phase I | Phase II | Phase III | NDA/MAA | Market |
|---|---|---|---|---|---|---|---|
| CAMCEVI (Leuprolide, FP-001) | |||||||
| Prostate Cancer, CAMCEVI 42 mg | | ||||||
| Prostate Cancer, CAMCEVI 21 mg | | ||||||
| Central Precocious Puberty | | ||||||
| FP-014 (Triptorelin) | |||||||
| Prostate Cancer | | ||||||
| FP-016 (Undisclosed) | |||||||
| Neurology/Psychiatry | | ||||||
| FP-004 (Buprenorphine) — Immediately Available for Partnering | |||||||
| Opioid Dependence/Pain | | ||||||
| FP-011 (Goserelin) — Immediately Available for Partnering | |||||||
| Breast Cancer | | ||||||
New Chemical Entities (NCE)
| Product / Indication | Research | Pre-clinical | Phase I | Phase II | Phase III | NDA/MAA | Market |
|---|---|---|---|---|---|---|---|
| FP-025 (MMP-12 Inhibitor) | |||||||
| POC Phase 2 study in allergic asthma patients | | ||||||
| Acute Exacerbations of COPD/ILD | | ||||||
| FP-020 (MMP-12 Inhibitor) | |||||||
| Sarcoidosis, Idiopathic pulmonary fibrosis (IPF), emphysema | | ||||||
| FP-045 (ALDH2 Activator) | |||||||
| POC Phase 1b/2 study in Fanconi Anemia (Pediatric formulation) | | ||||||
| Cardiovascular, Renal and Metabolism (CVRM) /Peripheral artery disease (PAD) | | ||||||
| FP-040 (ALDH2 Activator) | |||||||
| Central Nervous System (CNS) Diseases | | ||||||